ReproCELL Incorporated Logo

ReproCELL Incorporated

Provider of stem cell technology and services for research and regenerative medicine.

4978 | T

Overview

Corporate Details

ISIN(s):
JP3974770004
LEI:
Country:
Japan
Address:
横浜市港北区新横浜3−8−11

Description

ReproCELL Incorporated is a global company providing solutions for preclinical and clinical research, with a primary focus on stem cell technology, drug discovery, and regenerative medicine. The company's portfolio includes a wide range of products such as induced pluripotent stem cells (iPSCs), differentiated cells, 3D cell culture models, and specialized reagents like RNA-based reprogramming kits that avoid genomic integration. ReproCELL also offers extensive contract research services, including human tissue assays for evaluating drug efficacy and safety. A key area of expertise is the GMP-compliant manufacturing of clinical-grade iPSCs and iPSC-derived mesenchymal stem cells (iMSCs), supporting the development of advanced cell therapies. The company's tools and services are designed to help academic and commercial scientists accelerate the translation of research into clinical applications.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-13 07:35
確認書
Japanese 8.1 KB
2025-11-13 07:35
半期報告書-第24期(2025/04/01-2026/03/31)
Japanese 219.0 KB
2025-06-26 02:41
内部統制報告書-第23期(2024/04/01-2025/03/31)
Japanese 23.4 KB
2025-06-26 02:41
確認書
Japanese 8.1 KB
2025-06-26 02:40
有価証券報告書-第23期(2024/04/01-2025/03/31)
Japanese 1.1 MB
2024-11-13 07:31
確認書
Japanese 8.1 KB
2024-11-13 07:31
半期報告書-第23期(2024/04/01-2025/03/31)
Japanese 221.1 KB
2024-06-26 03:02
臨時報告書
Japanese 28.0 KB
2024-06-25 07:31
内部統制報告書-第22期(2023/04/01-2024/03/31)
Japanese 22.2 KB
2024-06-25 07:30
確認書
Japanese 8.2 KB
2024-06-25 07:29
有価証券報告書-第22期(2023/04/01-2024/03/31)
Japanese 1.2 MB
2024-05-23 08:02
臨時報告書
Japanese 20.0 KB
2024-02-09 07:24
確認書
Japanese 8.2 KB
2024-02-09 07:23
四半期報告書-第22期第3四半期(2023/10/01-2023/12/31)
Japanese 227.6 KB
2023-11-10 07:05
四半期報告書-第22期第2四半期(2023/07/01-2023/09/30)
Japanese 213.2 KB

Automate Your Workflow. Get a real-time feed of all ReproCELL Incorporated filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for ReproCELL Incorporated

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for ReproCELL Incorporated via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

1NKEMIA Logo
Biotechnology company providing R&D and services for the life sciences sector.
Spain
IKM
2cureX AB Logo
Develops an IVD test using 3D tumoroids to predict patient response to cancer drugs.
Sweden
2CUREX
Abera Bioscience AB Logo
Develops mucosal vaccines using a proprietary Outer Membrane Vesicle (OMV) platform.
Sweden
ABERA
Clinical-stage biopharma developing therapeutics for oncology and viral diseases.
South Korea
203400
ABL Bio Inc. Logo
Develops bispecific antibody therapeutics for oncology and neurodegenerative diseases.
South Korea
298380
Abpro Holdings, Inc. Logo
Clinical-stage biotech developing antibody therapeutics for oncology and ophthalmology.
United States of America
ABP
Absci Corp Logo
A generative AI drug creation company developing biologic medicines.
United States of America
ABSI
Achiko AG Logo
A digital services platform for cross-border business compliance and engagement.
Switzerland
ACHI
Active Biotech Logo
Biotechnology company developing drugs for oncology and inflammatory eye disorders.
Sweden
ACTI
Adagene Inc. Logo
Clinical-stage biotech developing antibody-based immunotherapies for oncology.
United States of America
ADAG

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.